Claims

A serine protease inhibitor of formula (I):

 R_2 X X Y L $Lp(D)_n$ (I)

wherein:

5

 R_2 is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, 10 optionally being substituted in the 3 and/or 4 position (in relation to the point of attachement of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO2- or R1, or the 15 substituents at the 3 or 4 positions taken together form a fused ring which is a 5 or \6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino hydrazido, alkylthio, alkenyl, alkynyl or R1;, and optionally substituted in the position 20 alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxx, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R2 cannot be aminoisoquinolyl;

each X independently is a C, N, O or S atom or a CO, 25 CR_{1a} , $C(R_{1a})_2$ or NR_{1a} group, at least one X being C, CO, CR_{1a} or $C(R_{1a})_2$;

each R_{la} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino,

30 acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl

 R_1 is as defined for R_{1a} , provided that R_1 is not

contd.

unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group; Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, optionally substituted by groups $R_{3i}X_{i}$;

each R_{3a} independently is R_{1C}, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, alkylthiazolyl, alkyloxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S; and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group), or -OCH₂O- which is bonded to two adjacent ring atoms in Cy;

 X_i is a bond, O, NH or CH_2 ;

 R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a} ; and

20 R_{lb}, R_{lc} and R_{lj} are as defined for R_{la};

L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; and

 $Lp(D)_n$ is of the formula:

25

$$-X_{a}$$
 X_{b} $-(L_{a})_{s}$ $-(G)_{t}$ $-(L_{b})_{u}$ $-R_{10}$

in which:

r is 1 or 2;

Xa is CH and Xb is N;

s, t and u are each 0 or 1;

 L_a and L_b are each independently selected from a single bond, C=O, O and NR_{1e}, in which R_{1e} is hydrogen or (1)


contol.

C) alkyl;

G is (1-6C)alkanediyl; and

R₁₀ is (1-6C)alkyl; (3-6C)cycloalkyl [which is unsubstituted or substituted by (1-6C)alkyl]; indanyl; 5 pyridyl; tetrahydropyranyl; tetrahydrothiopyranyl; phenyl {which as unsubstituted or substituted by one or two R3 groups [wherein R_3 is hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, 10 alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl, aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkylamino (optionally substituted by hydroxy, alkylamino, 15 alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl,

20 haloalkoxy, or haloalkyl]}, gyrrolinyl; or a group of formula:



in which v is 1,2 or 3; one of X_C and X_d is N and the other is CH or N (provided that when v is 1, X_C and X_d are not both N);

25 and R₁₁ is hydrogen, (1-6C)alkyl or when X_d is CH, hydroxy(1-6C)alkyl; provided that when t is 0, the sum of s and u is 1; when X_b is N, L_a is a bond or C=O; when X_c is N, L_b is a bond or C=O; when X_b and X_c are both N, t is 1; and when (L_a)_s-(G)_t-(L_b)_u represents an alkyl group and X_b and X_c both represent N, the alkyl group contains at least two chain carbon atoms;

or R_{10} is hydrogen and s, t and u are each 0;

contol 0^1

ļ.

01 01

or the compound of formula (I) that is 4-{[4-methoxybenzoyl-D,L-(2-trifluoromethylthiophenyl)-glycinyl)aminomethyl}-1-isopropylpiperidine; or a physiologically-tolerable salt thereof.

5

2. A serine protease inhibitor of formula (I):

$$R_2$$
 X
 X
 Y
 L
 $Lp(D)_n$

10 wherein:

R₂ is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachement of X-X) by halo, nitro, 15 thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, or the substituents at the 3 or 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or

20 heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j}, and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy,

25 alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R_2 cannot be aminoisoquinolyl;

each X independently is a C, N, O or S atom or a CO, CR_{1a} , $C(R_{1a})_2$ or NR_{1a} group, at least one X being C, CO, CR_{1a} or $C(R_{1a})_2$;

each R_{la} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino

contd Q¹

5

acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

 R_1 is as defined for R_{1a} , provided that R_1 is not unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group; Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group optionally substituted by groups R_{3a} or phenyl optionally substituted by R_{3a};

each R_{3a} independently is R_{1C}, amino, halo, cyano, nitro, 10 thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy or haloalkyl; and

 R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ;

L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group; and

 $Lp(D)_n$ is of the formula:

 X_a X_b $(L_a)_s$ - $(G)_t$ - $(L_b)_u$ - R_{10}

20

15

in which:

r is 1 or 2;

Xa is CH and Xb is N;

s, t and u are each 0\or 1;

La and Lb are each independently selected from a single bond, C=O, O and NR_{1e}, in which R_{1e} is hydrogen or (1-6C)alkyl;

G is (1-6C) alkanediyl; and

antd.

 R_{10} is (1-6C)alkyl; (3-6C)cycloalkyl [which is unsubstituted or substituted by (1-6C) alkyl]; indanyl; pyridyl; \tetrahydropyranyl; tetrahydrothiopyranyl; phenyl {which is unsubstituted or substituted by one or two R3 groups 5 [wherein R₃ \(\) is hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, 10 acyloxymethoxycarbonyl, aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkysulphenyl, triazolyl, 15 imidazolyl, tetrazolyl, hydraxido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl,

haloalkoxy or haloalkyl]}, pyrrolikyl; or a group of formula:

in which v is 1, 2 or 3; one of X_C and X_d is N and the other is CH or N, provided that when v is 1, X_C and X_d are not both N; and R_{11} is hydrogen, (1-6C)alkyl or when X_d is CH, hydroxy(1-6C)alkyl; provided that when t is 0, the sum of s and u is 1; when X_b is N, L_a is a bond or C=O; when X_C is N,

alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl,

25 L_b is a bond or C=O; when X_b and X_c are both N, t is 1; and when $(L_a)_s$ - $(G)_t$ - $(L_b)_u$ represents and alkyl group and X_b and X_c both represent N, the alkyl group contains at least two chain carbon atoms,

or a physiologically-tolerable salt thereof.

30 3. A serine protease inhibitor according to claim 1 or claim

contd U¹

2, wherein R³ is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, t-butyl, pentyl, 2-pentyl, 3-pentyl, isopropylaminomethyl, dimethylamino-methyl, diethylaminomethyl, dimethylaminoethyl,

- 5 acetyl, hydroxymethyl, hydroxyethyl, carboxy, carboxy(1-5C)alkyl, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminocarbonyl, aminocarbonyl(1-5C)alkyl, methylamino, dimethylamino, ethylamino, formylamino, acetylamino, amino,
- 10 fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, isopropylsulphonyl, methylsulphenyl,1,2,4-triazol-2-yl, 1,2,4-triazol-4-yl, 1,2,3-triazol-4-yl, 1,3-imidazol-1-yl,1,3-imidazol-4-yl, tetrazol-1-yl, tetrazol-5-yl, methylsulphonamido, ethylsulphonamido,
- 15 propylsulphonamido, methylaminosulphonyl, ethylaminosulphonyl, propylaminosulphonyl, aminosulphonyl, trifluoromethyl, and trichloromethyl.
- 4. A compound according to any of claims 1 to 3 wherein r is 20 2.
 - 5. A compound according to claim 1 wherein $Lp(D)_n$ is of the formula:

5 M

N-R (CH₂)_q

25 wherein:

q is 1 or 2;

 R_S is hydrogen, $-(CH_2)_C - R_C$, $-CHR_eR_f$, or $-CH_2 - CHR_eR_f$ [c is 0, 1 or 2; wherein R_C is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 ,

methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and Re and Rf are independently hydrogen or C1-3alkyl; or $CHR_{e}R_{f}$ is (3-6C) cycloalkyl (which may bear a methyl, ethyl or 5 hydroxymethyl substituent at the 3- or 4-position, provided the substituent is not bonded to the CH group which is bonded to L), tetrahydxopyranyl, tetrahydrothiopyranyl, pyrrolidinyl (which may bear a 1-methyl substituent), piperidinyl (which may bear a 1-methyl substituent) (provided that the 10 tetrahydropyranyl, tetrahydrothiopyranyl, pyrrolidinyl and piperidinyl rings are not linked to the piperidin-1,4-diyl group through a ring nitrogen atom or a ring carbon atom adjacent to a ring oxygen, sulfur or nitrogen atom) or indan-2-yl].

6. A compound according to any one of claims 1 to 5 wherein L is CONH, CH2NHCO, CONHCH2, CONHCH2CH2 or CON (Me) CH2.

7. A serine protease inhibitor according to claim 2 wherein -L-Lp(D)_n is of the formula:

wherein

q is 1 or 2;

s is 0 or 1; and

Rs is - (CH₂)_C-R_C, -CHR_eR_f, or -CH₂-CHR_eR_f [wherein c is 1 25 or 2; R_C is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, CONH2, SO2NH2, methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and R_e and R_f are independently

15

hydrogen or C1-3alkyl; or CHReRf is cyclopentyl (which may bear a methyl, ethyl or hydroxymethyl substituent at the 3- or 4-position), cyclohexyl (which may bear a methyl, ethyl or hydroxymethyl substitutent at the 3- or 4-position),

5 tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, pyrrolidin-3yl (which may bear a 1-methyl substituent), piperidin-4-yl (which may bear a 1-methyl substituent), or indan-2-yl].

A compound according to any of claims 5 to 7 wherein q is 2.

9. \mathbb{A} compound according to claim 1 or claim 2 wherein $\mathbb{A}(D)_n$ is selected from one of the following formulae:

15

 a^3

<u>_</u>__

NJ

wherein m represents 0 or 1.

5 10. A compound according to any of claims 5 to 7 wherein R_S is selected from: hydrogen, methyl, ethyl, prop-2-yl, but-2-yl, pent-3-yl, hept 4-yl, cyclopentyl, cyclohexyl, cyclohexylmethyl, 1-methylpiperidin-4-yl, tetrahydropyran-4-yl, tetrahydrothiopyran-4-yl, phenyl, benzyl, pyrid-2-yl, pyrid-3-yl, pyrid-3-yl, pyrid-3-ylmethyl, pyrid-4-ylmethyl and

0 pyrid-3-yl, pyrid-4-yl, pyrid-3-ylmethyl, pyrid-4-ylmethyl and indan-2-yl.

11. A compound according to any one of claims 1 to 10 wherein R_2 is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl,

- 15 benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl (each of which is optionally substituted as defined in claim 1).
- 12. A compound according to any one of claims 1 to 11 wherein 20 optional substituents for R₂ are selected from: fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy, trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano, trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino, carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH₂), 25 aminomethyl, methoxy and ethoxy.
 - 13. A compound according to any one of claims 1 to 12 wherein R_2 is selected from one of the formula (A') to (H')

contd a³

$$R_{14}$$
 R_{15}
 R_{13}
 R

wherein X_4 is 0 or S, R_{13} is selected from hydrogen, fluoro, chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino.

14. A compound according to claims 1 to 13, wherein R₂ is 4-methoxyphenyl, 3-amino-4-chlorophenyl, indol-2-yl, 5-chloroindol-2-yl, indol-6-yl, 3-chloroindol-6-yl or 3-methylindol-6-yl.

15. A compound according to any one of claims 1 to 14 wherein -X-X- is -CONH-.

contal a

No. A compound according to any one of claims 1 to 15 wherein Y is CH.

- 5 17. A compound according to any one of claims 1 to 16 wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl,
- 10 pridazinyl, quinolyl, isoquinolyl benzofuryl, benzothienyl or cycloalkyl group, or a phenyl group substituted by $R_{3i}X_i$ in which X_i is a bond, O, NH or CH_2 and R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a} .
- 15 18. A compound according to any one of claims 1 to 17 wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group
- 19. A compound according to any one of claims 1 to 18 wherein 20 R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, alkylamino,
- 25 alkoxy, oxo, aryl or cycloalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), for amino, halo, cyano, nitro,thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido,
- 30 alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is 0 or S; and R^{11} and R^{12} are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or

morpholino group) and $-OCH_2O-$ which is bonded to two adjacent ring atoms in Cy.

- 20. A compound according to any one of claims 1 to 19 wherein 5 R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl,
- 10 alkoxycarbonylamino, alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), aminoalkyl (substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphonamido,

ļ.i.

- 15 alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl.
 - R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl,
- 20 hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl, CONH2, CH2CONH2, acetylamino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, bromo, cyano,
- 25 nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, methylsulphonyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-1-ylcarbonyl and -OCH₂O-30 (which is bonded to two adjacent ring atoms in Cy).
 - 22. A compound according to any one of claims 1 to 19 wherein R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl,

Q4

hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl, $CONH_2$, CH_2CONH_2 , acetylamino, methoxycarbonylamino, ethoxycarbonylamino, t-

butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro, thiol methylthio, methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and trifluoromethyl.

10

cj Fr

23. A compound according to any one of claims 1 to 22 wherein Cy is selected from:

15

wherein:

X' is selected from O, S and NMe;

X'' is selected from O and S

ļ.ā

 χ'' is selected from O, S, NH and NMe;

Y'\ is selected from hydrogen, amino and methyl;

-183 -

Ro is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl and 5 methylsulphonyl;

R_m is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl methoxy, methylthio, methylsulphinyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is O or S and R^{11} and R^{12} 10 are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group); Rp is selected from hydrogen and fluoro; or R_O and R_m or R_m and R_D form an -OCH₂O- group; or 15 Ro and Rm together with the king to which they are attached form a 5 or 6 membered aryl or\heteroaryl ring (wherein the

one of R_{O1} and R_{O2} is hydrogen\and the other is R_O;

heteroary ring contains 1 or 2 heteroatoms selected from

nitrogen, oxygen and sulfur);

- 24. A compound according to any one of claims 1 to 19 wherein Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, pyrid-3-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl,
- 25 thiazol-4-yl, thiazol-5-yl, naphthyl, isoquin\lin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl, and quinolin-8-yl.
- A compound as claimed in any one of Claims 1 to 24, in 30 which the alpha atom in Y is carbon and has the conformation that would result from construction from a $D-\alpha$ -aminoacid $NH_2-CR_{1h}(Cy)-COOH$ where the NH_2 represents part of X-X
 - A pharmaceutical composition, which comprises a compound 26.

contd Q4

as claimed in any one of claims 1 to 25 together with at least one pharmaceutically acceptable carrier or excipient.

- 27. A compound as claimed in any one of claims 1 to 25 for 5 use in therapy.
 - 28. Use of a compound as claimed in any one of claims 1 to 25 for the manufacture of a medicament for the treatment of a thrombotic disorder.

 l_{min}

29. A method of treatment of a human or non-human animal body to combat a thrombotic disorder, which comprises administering to said body an effective amount of a compound as claimed in claim 1.

15

30. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 25 for use to combat a thrombotic disorder.

20 31. A compound of formula I as claimed in claim 1 and named in any of the Examples herein, or a physiologically-tolerable salt thereof.

add Bi